Top Markets
Coin of the day
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Rang in Aktien #29651
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Aktienkurs
$0.68377137
Zuletzt synchronisiert: 2023-05-23
Marktkapitalisierung
$20.23M
Veränderung (1 Tag)
-0.60%
Veränderung (1 Jahr)
0.00%
Land
SE
Handel Medivir AB (publ) (MVIR-B)

Kategorie

Aktien-Split-Historie für Medivir AB (publ) (MVIR-B)
Die Aktie Medivir AB (publ) (Symbol: MVIR-B) durchlief insgesamt 0 Aktiensplits.
Der letzte Aktiensplit fand am Aug 19, 2026 statt.
Eine MVIR-B-Aktie, die vor dem Aug 19, 2026 gekauft wurde, entspricht heute 0 MVIR-B-Aktien.
Liste der Aktiensplits
Jahr Aktien-Split Multiplikator Kumulierter Multiplikator
Nicht genügend Daten für die angegebenen Daten.
Aktiensplits ähnlicher Unternehmen oder Wettbewerber
Unternehmen Anzahl der Aktiensplits Kumulierter Multiplikator Land
1 x2
US
0 -
NL
1 x3
AU
0 -
CH
0 -
KR